Category: Policy Perspectives

These papers discuss important health policy topics within the scope of the journal. They may reflect conceptual pieces or reviews of the literature.

THE PROBLEM OF REIMBURSEMENT FOR SINGLE-USE DEVICES IN ASIA-PACIFIC COUNTRIES

Seoul, South Korea – In Asia-Pacific countries, as elsewhere, less than 6% of total health care spending per capita is on medical devices, though these technologies often make critical contributions to the delivery of clinical and economic benefits to both

Posted in ISPOR News & Press, Policy Perspectives, Value in Health Regional Issues Tagged with: , , ,

SUCCESS FEE: A NOVEL TOOL FOR THE SUSTAINABILITY OF NOVEL EXPENSIVE THERAPIES

Catania, Italy – To guarantee rapid patient access to high cost, innovative therapies, policy makers have introduced cost-containment strategies based on the partial or total reimbursements of a drug price. Under these agreements, market access for a drug is granted

Posted in Announcements, Policy Perspectives, Value in Health Tagged with: , , , , , , ,

A New Approach To Korea’s Reimbursement Coverage And Pricing Rules For Medical Devices Long Overdue

Seoul, South Korea – Since 1989, Korea has had a comprehensive National Health Insurance system, which also covers most implantable and disposable medical devices. Although medical devices account for only about 4% of the total budget, considerable attention is paid to

Posted in Policy Perspectives, Value in Health Tagged with: , , , , ,

Improving Clinical Trial Participation Through Patient-Centered Trial Design

Baltimore, MD, USA – Many people are reluctant to participate in clinical trials.  This reluctance stems from the perception of risk while not seeing any clear benefit to participation.  The exception is when an individual has a condition for which there

Posted in Policy Perspectives, Value in Health Tagged with: , , , , ,

A Value Proposition For Specialty Medications

Newark, DE, USA – Hospitals, physicians, payers and patients face economic and ethical decisions about the use of biotechnology drugs, commonly called specialty medications. Medicare, physician guidelines and consensus statements currently include specialty drugs without an assessment of value, resulting in

Posted in Policy Perspectives, Value in Health Tagged with: , , , ,

Where Do We Need Best Practices In Development And Reimbursement Of Personalized Medicine?

Durham, NC, USA – Personalized medicine technologies are currently caught between high expectations of improving health outcomes and uncertainty about navigating the rapidly changing regulatory and reimbursement environment. This is because they do not fit neatly into the existing routes by

Posted in Policy Perspectives, Value in Health Tagged with: , , , ,

Drugs For Rare Diseases: How To Fund Them?

Toronto, ON, Canada– Enzyme replacement therapies for rare inherited metabolic diseases are among the most expensive drugs in the world and have created a dilemma for public drug payers.

Posted in Policy Perspectives, Value in Health Tagged with: , , , ,